432 related articles for article (PubMed ID: 15878443)
1. Trends in linezolid susceptibility patterns in 2002: report from the worldwide Zyvox Annual Appraisal of Potency and Spectrum Program.
Ross JE; Anderegg TR; Sader HS; Fritsche TR; Jones RN
Diagn Microbiol Infect Dis; 2005 May; 52(1):53-8. PubMed ID: 15878443
[TBL] [Abstract][Full Text] [Related]
2. Trends in linezolid susceptibility patterns: report from the 2002-2003 worldwide Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program.
Anderegg TR; Sader HS; Fritsche TR; Ross JE; Jones RN
Int J Antimicrob Agents; 2005 Jul; 26(1):13-21. PubMed ID: 15967640
[TBL] [Abstract][Full Text] [Related]
3. Zyvox Annual Appraisal of Potency and Spectrum program: linezolid surveillance program results for 2008.
Jones RN; Ross JE; Bell JM; Utsuki U; Fumiaki I; Kobayashi I; Turnidge JD
Diagn Microbiol Infect Dis; 2009 Dec; 65(4):404-13. PubMed ID: 19913683
[TBL] [Abstract][Full Text] [Related]
4. Oxazolidinone susceptibility patterns in 2004: report from the Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations.
Jones RN; Ross JE; Fritsche TR; Sader HS
J Antimicrob Chemother; 2006 Feb; 57(2):279-87. PubMed ID: 16326811
[TBL] [Abstract][Full Text] [Related]
5. Zyvox Annual Appraisal of Potency and Spectrum Program Results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from 16 countries.
Jones RN; Fritsche TR; Sader HS; Ross JE
Diagn Microbiol Infect Dis; 2007 Oct; 59(2):199-209. PubMed ID: 17908617
[TBL] [Abstract][Full Text] [Related]
6. Stability of linezolid activity in an era of mobile oxazolidinone resistance determinants: results from the 2009 Zyvox® Annual Appraisal of Potency and Spectrum program.
Biedenbach DJ; Farrell DJ; Mendes RE; Ross JE; Jones RN
Diagn Microbiol Infect Dis; 2010 Dec; 68(4):459-67. PubMed ID: 21094428
[TBL] [Abstract][Full Text] [Related]
7. Oxazolidinone susceptibility patterns for 2005: International Report from the Zyvox Annual Appraisal of Potency and Spectrum Study.
Ross JE; Fritsche TR; Sader HS; Jones RN
Int J Antimicrob Agents; 2007 Mar; 29(3):295-301. PubMed ID: 17239570
[TBL] [Abstract][Full Text] [Related]
8. ZAAPS International Surveillance Program (2007) for linezolid resistance: results from 5591 Gram-positive clinical isolates in 23 countries.
Jones RN; Kohno S; Ono Y; Ross JE; Yanagihara K
Diagn Microbiol Infect Dis; 2009 Jun; 64(2):191-201. PubMed ID: 19500528
[TBL] [Abstract][Full Text] [Related]
9. Surveillance of linezolid resistance in Germany, 2001-2002.
Brauers J; Kresken M; Hafner D; Shah PM;
Clin Microbiol Infect; 2005 Jan; 11(1):39-46. PubMed ID: 15649302
[TBL] [Abstract][Full Text] [Related]
10. Linezolid surveillance program results for 2008 (LEADER Program for 2008).
Farrell DJ; Mendes RE; Ross JE; Jones RN
Diagn Microbiol Infect Dis; 2009 Dec; 65(4):392-403. PubMed ID: 19913682
[TBL] [Abstract][Full Text] [Related]
11. Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) program: report of linezolid activity over 9 years (2004-12).
Mendes RE; Hogan PA; Streit JM; Jones RN; Flamm RK
J Antimicrob Chemother; 2014 Jun; 69(6):1582-8. PubMed ID: 24468866
[TBL] [Abstract][Full Text] [Related]
12. LEADER surveillance program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from the United States (50 medical centers).
Jones RN; Fritsche TR; Sader HS; Ross JE
Diagn Microbiol Infect Dis; 2007 Nov; 59(3):309-17. PubMed ID: 17720350
[TBL] [Abstract][Full Text] [Related]
13. ZAAPS Program results for 2010: an activity and spectrum analysis of linezolid using clinical isolates from 75 medical centres in 24 countries.
Flamm RK; Farrell DJ; Mendes RE; Ross JE; Sader HS; Jones RN
J Chemother; 2012 Dec; 24(6):328-37. PubMed ID: 23174097
[TBL] [Abstract][Full Text] [Related]
14. Multicenter assessment of the linezolid spectrum and activity using the disk diffusion and Etest methods: report of the Zyvox(R) antimicrobial potency study in Latin America (LA-ZAPS).
Ballow CH; Biedenbach DJ; Rossi F; Jones RN;
Braz J Infect Dis; 2002 Jun; 6(3):100-9. PubMed ID: 12144745
[TBL] [Abstract][Full Text] [Related]
15. [In vitro susceptibility to linezolid in methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus strains].
Efe S; Sinirtaş M; Ozakin C
Mikrobiyol Bul; 2009 Oct; 43(4):639-43. PubMed ID: 20084917
[TBL] [Abstract][Full Text] [Related]
16. Linezolid resistance since 2001: SENTRY Antimicrobial Surveillance Program.
Mutnick AH; Enne V; Jones RN
Ann Pharmacother; 2003 Jun; 37(6):769-74. PubMed ID: 12773059
[TBL] [Abstract][Full Text] [Related]
17. Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
Moet GJ; Jones RN; Biedenbach DJ; Stilwell MG; Fritsche TR
Diagn Microbiol Infect Dis; 2007 Jan; 57(1):7-13. PubMed ID: 17059876
[TBL] [Abstract][Full Text] [Related]
18. Susceptibility to tigecycline and linezolid among gram-positive isolates collected in the United States as part of the tigecycline evaluation and surveillance trial (TEST) between 2004 and 2009.
Dowzicky MJ
Clin Ther; 2011 Dec; 33(12):1964-73. PubMed ID: 22078154
[TBL] [Abstract][Full Text] [Related]
19. Antimicrobial resistance and molecular epidemiology of vancomycin-resistant enterococci from North America and Europe: a report from the SENTRY antimicrobial surveillance program.
Deshpande LM; Fritsche TR; Moet GJ; Biedenbach DJ; Jones RN
Diagn Microbiol Infect Dis; 2007 Jun; 58(2):163-70. PubMed ID: 17368801
[TBL] [Abstract][Full Text] [Related]
20. United States resistance surveillance results for linezolid (LEADER Program for 2007).
Jones RN; Ross JE; Castanheira M; Mendes RE
Diagn Microbiol Infect Dis; 2008 Dec; 62(4):416-26. PubMed ID: 19022153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
